Vetter Combines Laboratory Portfolio into Single Site

Article

Pharmaceutical Technology's In the Lab eNewsletter

In the Lab eNewsletterPharmaceutical Technology\'s In the Lab eNewsletter-02-05-2020
Volume 15
Issue 2

The new 1800-m2 building houses more than 50 employees and features non-GMP laboratory space and a GMP analytical laboratory.

Vetter, a contract development and manufacturing organization based in Germany, announced on Jan. 30, 2020 that it has combined its development laboratories into one site located in Ravensburg, Germany.

The new 1800-m2 building houses more than 50 employees and features process development capabilities, functional and specification testing of packaging systems, and chemical-analytical, biochemical analysis, and particle characterization abilities, according to a company press release. The non-GMP laboratory space and the GMP analytical laboratory will also enable increased capacity and optimized workspaces.

The company decided to combine the labs to improve workflow and give employees the opportunity to share expertise, simplify information exchange, leverage synergies, and reinforce a positive work atmosphere, the release said. Customers will also benefit from the venture through daily support in complex development projects.

“Our customers are excited and impressed with the new and modern development laboratories and their increased capacity. Now they can follow a complete development process and its individual steps, since it proceeds throughout the labs, all within the same building,” said Dr. Claus Feussner, senior vice-president of Development Services, Vetter, in the press release. “Expansion will continue within the building throughout the year and includes more lab space and the provision of additional innovative analytical equipment and lyophilizer capacity.

Source: Vetter

 

 

 

Recent Videos
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Christian Dunne, director of Global Corporate Business Development at ChargePoint Technology
Drug Digest: Focusing on Solid Dosage Trends and Demand
Behind the Headlines, episode 7
Related Content